Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation

Heart

Volumn 98, Issue 7, 2012, Pages 573-578

  Kansal, Anuraag R ^a   Sorensen, Sonja V ^a   Gani, Ray ^b   Robinson, Paul ^b   Pan, Feng ^a   Plum, Jonathan M ^c   Cowie, Martin R ^d  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b BOEHRINGER INGELHEIM LTD   (United Kingdom)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DABIGATRAN ETEXILATE; WARFARIN;

AGED; AGING; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; UNITED KINGDOM;

AGED, 80 AND OVER; ANTITHROMBIN PROTEINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; COST-BENEFIT ANALYSIS; DRUG COSTS; EMBOLISM; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; MALE; MODELS, ECONOMIC; PYRIDINES; STROKE;

EID: 84858598110     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-300646     Document Type: Article

References (31)

1. National Health Service. Quality and Outcomes Framework. 2011. http://www. isdscotland.org/isd/6430.htm; http://www.wales.nhs.uk/sites3/page. cfm? orgid=480&pid=6063; http://www.ic.nhs.uk/statistics-and-data- collections/ supporting-information/audits-and-performance/the-quality-and- outcomes-framework/ qof-2009-10/data-tables/prevalence-data-tables; http://www.dhsspsni. gov.uk/national-prevalence-day-report-april-2011.pdf (accessed 14 Apr 2011).
2. DeWilde S, Carey IM, Emmas C, et al. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 2006;92:1064-70. (Pubitemid 44131331)
3. National Collaborating Centre for Chronic Conditions. Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. London: Royal College of Physicians, 2006.
4. Luengo-Fernandez R, Gray AM, Rothwell PM. Population-based study of determinants of initial secondary care costs of acute stroke in the United Kingdom. Stroke 2006;37:2579-87. (Pubitemid 44454682)
5. Frost L, Engholm G, Johnsen S, et al. Incident thromboembolism in the aorta and the renal, mesenteric, pelvic, and extremity arteries after discharge from the hospital with a diagnosis of atrial fibrillation. Arch Intern Med 2001;161:272-6. (Pubitemid 32102396)
6. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67. (Pubitemid 351650486)
7. British National Formulary (BNF). Warfarin Sodium: Drug Interactions. BNF 57. 2009. http://www.bnf.org.uk/bnf/ (accessed 20 May 2011).
8. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
9. Gallagher AM, Rietbrock S, Plumb J, et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008;6:1500-6.
10. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS Focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011;57:1330-7.
11. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27.
12. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
13. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875-6.
14. Cairns JA, Connolly S, McMurtry S, et al. Canadian cardiovascular society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011;27:74-90.
15. Sorensen SV, Dewilde S, Singer DE, et al. Cost-effectiveness of warfarin: trial versus 'real-world' stroke prevention in atrial fibrillation. Am Heart J 2009;157:1064-73.
16. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011;105:908-19.
17. European Medicines Agency. European Public Assessment Report: Pradaxa. 2011. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/ 000829/human-med-000981.jsp&murl=menus/medicines/medicines. jsp&mid=WC0b01ac058001d125 (accessed 4 Oct 2011).
18. van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006;129:1155-66.
19. Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011;106:968-77.
20. National Institute for Health and Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal. London, UK: National Institute for Health and Clinical Excellence, 2008.
21. Roskell NS, Lip GY, Noack H, et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010;104:1106-15.
22. Sullivan PW, Arant TW, Ellis SL, et al. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics 2006;24:1021-33. (Pubitemid 44497473)
23. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996;156:1829-36. (Pubitemid 26295228)
24. MIMS Online. Drug costs from MIMS. London, UK: Haymarket Medical Media, 2010. (2011 for dabigatran).
25. National Institute for Health and Clinical Excellence (NICE). Costing Report: Implementing NICE Guidance in England. Atrial Fibrillation: The Management of Atrial Fibrillation. NICE Clinical Guideline 36. London, UK: National Institute for Health and Clinical Excellence, 2006. http://www.nice.org.uk/nicemedia/pdf/ CG036costingreport.pdf (accessed 5 Mar 2011).
26. Department of Health. NHS Reference Costs 2007-2008. London, UK: Department of Health 2009.
27. Luengo-Fernandez R, Yiin G, Gray AM, et al. Population-based study of acute- and long-term care costs after stroke in patients with AF. Int J Stroke, In press.
28. Curtis L. Unit Costs of Health and Social Care 2009. Personal Social Services Research Unit. University of Kent, 2009 (accessed 20 May 2011). http://www.pssru. ac.uk/pdf/uc/uc2009/uc2009.pdf
29. Freeman JV, Turakhia MP. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:570-1.
30. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011;123:2562-70.
31. Miller PS, Andersson FL, Kalra L. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? Stroke 2005;36:360-6. (Pubitemid 40170823)